A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1176-1180

  Erkan, Doruk ^a   Willis, Rohan ^b   Murthy, Vijaya L ^b   Basra, Gurjot ^b   Vega, Joann ^a   Ruiz Limón, Patricia ^b   Carrera, Ana Laura ^b   Papalardo, Elizabeth ^b   Martínez Martínez, Laura Aline ^b   González, Emilio B ^b   Pierangeli, Silvia S ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BIOLOGICAL MARKER; CD40 LIGAND; CREATINE KINASE; FLUINDOSTATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHOLIPID ANTIBODY; PREDNISONE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PILOT STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANTIPHOSPHOLIPID ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; CYTOKINES; INFLAMMATION; TREATMENT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CYTOKINES; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899916939     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203622     Document Type: Article

References (21)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4: 295-306.
2. Simantov E, LaSala J, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96: 2211-19.
3. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84: 388-95.
4. Gharavi AE, Pierangeli SS, Colden-Stanfield , et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999;163: 2922-7. (Pubitemid 29399224)
5. Del Papa N, Guidali L, Sala A, et al. Endothelial cell target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-β2glycoprotein I and induce endothelial cell activation. Arthritis Rheum 1997;40: 551-61.
6. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000;43: 55-64. (Pubitemid 30368213)
7. Zhou H, Woldberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104: 2353-8. (Pubitemid 39331833)
8. Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52: 1545-54. (Pubitemid 40663946)
9. Forastiero RR, Martinuzzo ME, De Larranaga G. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 2005;14: 129-36. (Pubitemid 40327663)
10. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44: 2870-8. (Pubitemid 34016207)
11. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2: 1558-63. (Pubitemid 40186171)
12. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48: 3272-9. (Pubitemid 37409342)
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;10: 1737-40.
15. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147: 117-23.
16. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24: 303-8. (Pubitemid 27104093)
17. Camargo JF, Correa PA, Castiblanco J, et al. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. Genes Immun 2004;5: 609-14. (Pubitemid 40045298)
18. Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153: 1328-32. (Pubitemid 24228525)
19. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007;110: 2423-31. (Pubitemid 47523163)
20. Desai-Mehta A, Lu L, Ramsey-Goldman R, et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97: 2063-73. (Pubitemid 26143961)
21. Lopez-Pedrera C, Ruiz-Rimon P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011;70: 675-82.